COLORADO
Department of Health Care Policy & Financing

Drug Utilization Review Board
MEETING AGENDA
August 9, 2022
Open Session 1:00 pm to 5:00 pm

Zoom Link will be posted prior to the meeting at
https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board

Health First Colorado, Colorado's Medicaid program

DUR Board Members	DUR Team
Alison Shmerling, MD, MPH (Chair)	Jeffrey Taylor, PharmD (HCPF)
Liza Claus, PharmD (Vice Chair)	Julia Rawlings, PharmD (CO-DUR)
Todd Brubaker, DO	Robert L Page II, PharmD, MSPH (CO DUR)
Brian Jackson, MD, MA	Gina Moore, PharmD, MBA (CO DUR)
Shilpa Klocke, PharmD	Heather Anderson, PhD (CO DUR)
Patricia Lanius, BSPharm, MHA	Garth Wright, MPH (CO DUR)
Kenneth MacIntyre, DO	Vanessa Patterson, MPH (CO DUR)
Ingrid Pan, PharmD	

1. **Call to Order**
2. **Roll Call and Introductions**
3. **Virtual Meeting Information and General Announcements**
4. **Colorado Department of Health Care Policy and Financing Updates**
5. **Final Approval of Minutes from the May 10, 2022 Meeting**
7. **Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest**

   Presentations:
   - Agenda items must be approved in advance, including requests to present information. Please contact DUR Pharmacist Jeffrey Taylor at jeffrey.taylor@state.co.us
   - Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours prior to the start of the meeting.

6. **Clinical Updates and General Orders**
   - FDA New Product & Safety Updates
   - Quarterly Module Summaries
   - Retrospective DUR Letters and Reports
   - Quarterly Drug Utilization Reports

COLORADO
Department of Health Care Policy & Financing

8. **New Business** (open for public testimony and DUR Board review)

Proposed Criteria for PDL Drug Classes Scheduled for Review

- Contraceptives – Oral, Topical
- Diabetes Management Class, Insulins
  - Rapid-Acting Insulins
  - Long-Acting Insulins
  - Insulin Mixtures
- Diabetes Management Class, Non-Insulin
  - GLP-1 Analogues
  - SGLT-2is
- Glucagon, Self-administered
- Growth Hormones

Mass review drug classes*

- Androgenic Agents, Topical, Injectable, Oral
- Bone Resorption Suppression and Related Agents
- Diabetes Management Class, Insulins
  - Short-Acting Insulins
  - Intermediate-Acting Insulins
- Diabetes Management Class, Non-Insulins
  - Amylin
  - Biguanides
  - DPP-4is
  - Meglitinides
  - Thiazolidinediones (TZDs)
  - Combinations
- Estrogen Agents – Oral/Transdermal, Injectable
- Phosphate Binders
- Prenatal Vitamins/Minerals
- Antihyperuricemics
- Benign Prostatic Hyperplasia (BPH) Agents
- Overactive Bladder Agents

* *Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.*

COLORADO
Department of Health Care Policy & Financing

9. Proposed Prior Authorization Criteria for Non-PDL Products Managed Under the Pharmacy Benefit

- Pyrukynd (mitapivat)
- Vijoice (alpelisib)
- Camzyos (mavacamten)

10. Proposed Prior Authorization Criteria for Non-PDL Physician Administered Drug Products Managed Under the Pharmacy Benefit and Medical Benefit (J-Codes listed for medical benefit management)

- J3241 Tepezza (teprotumumab)
- J1303 Ultomiris (ravulizumab)
- J2796 Nplate (romiplostim)
- J3032 Vyepti (eptinezumab)
- Select Agents Used for Lupus:
  - J0490 Benlysta (belimumab)
  - J0491 Saphnelo (anifrolumab)
- Select Agents Used for Pompe Disease:
  - J0221 Lumizyme (alglucosidase alfa)
  - J0219 Nexviazyme (avalglucosidase)
- Select Agents Used for Multiple Sclerosis:
  - J2350 Ocrevus (ocrelizumab)
  - J2323 Tysabri (natalizumab)
  - J0202 Lemtrada (alemtuzumab)

11. Proposed Prior Authorization Criteria for Non-PDL Physician Administered Drug Products Managed Under the Medical Benefit

- J0178 Eylea (aflibercept)

COLORADO
Department of Health Care Policy & Financing

12. Adjournment

Next meeting date
November 8, 2022
1:00 pm to 5:00 pm

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator or send an email to hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.